


β-catenin-IN-6

Cat. No.:	HY-10834		
CAS No.:	1039731-99-1		
Molecular Formula:	C ₂₂ H ₁₉ ClN ₆ O		
Molecular Weight:	418.88		
Target:	β-catenin		
Pathway:	Stem Cell/Wnt		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (238.73 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	2.3873 mL	11.9366 mL	23.8732 mL
5 mM	0.4775 mL	2.3873 mL	4.7746 mL
10 mM	0.2387 mL	1.1937 mL	2.3873 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

β-catenin-IN-6 is a β-catenin inhibitor, targeting to canonical Wntless-related integration site signaling pathway. β-catenin-IN-6 inhibits human colorectal cancer cells proliferation, as well as in a β-catenin/RK3E mouse model^{[1][2]}.

In Vitro

β-catenin-IN-6 (compound 9) (24 h) inhibits in LoVo and HT29 cells with IC₅₀s of 1.4 μM and 1.37 μM, respectively. β-catenin-IN-6 shows cell growth inhibition against several human colorectal cancer lines^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

β-catenin-IN-6 (compound 9) displays poor bioavailability^[1].
β-catenin-IN-6 (18.75 mg/kg; ip; once daily for 7 days) decreases tumor volume in mouse model, without affecting body weight^[1].
β-catenin-IN-6 (compound 13) (150 mg/kg; ip; once per week) suppresses xenograft tumor growth in a β-catenin/RK3E mouse model^[2].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Nude mice bearing subcutaneous β -catenin/ RK3E tumors ^{[1][2]}
Dosage:	18.75 mg/kg, 37.5 mg/kg, 75.1 mg/kg, 150 mg/kg
Administration:	IP; once daily for 7 days
Result:	Inhibited tumor growth up to 66% in mouse model. Showed dose-dependently inhibition on tumor growth and volume.

REFERENCES

[1]. Dehnhardt CM, et al. Design and synthesis of novel diaminoquinazolines with in vivo efficacy for beta-catenin/T-cell transcriptional factor 4 pathway inhibition. J Med Chem. 2010 Jan 28;53(2):897-910.

[2]. McCoy MA, et al. Biophysical Survey of Small-Molecule β -Catenin Inhibitors: A Cautionary Tale. J Med Chem. 2022 May 26;65(10):7246-7261.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA